Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443579 in Relapsed or Refractory Hematological Malignancies
NCT05086315Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of SAR443579 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Sanofi. Started Dec 2021; status: terminated.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT05086315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086315.